SC
INBX icon

SummitTX Capital’s Inhibrx INBX Stock Holding History

SummitTX Capital’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.27M Buy
137,821
+54,936
+66% +$4.07M 0.29% 74
2025
Q4 		$6.55M Buy
82,885
+28,742
+53% +$1.96M 0.2% 123
2025
Q3 		$1.82M Buy
+54,143
New +$1.33M 0.08% 276

Other funds holding INBX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

SummitTX Capital's INBX Position: Q1 2026 in Review

SummitTX Capital increased its Inhibrx (INBX) stake by 66% in Q1 2026, buying an estimated $4.07M and bringing the position to 137,821 shares worth $9.27M. The position accounts for 0.29% of the portfolio, ranked #74.

SummitTX Capital first reported a position in INBX in Q3 2025 and has held it in 3 quarters since. 135 funds tracked by Wall St. Rank hold INBX as of Q1 2026.

  • SummitTX Capital held 137,821 shares of Inhibrx worth $9.27M as of Q1 2026.
  • SummitTX Capital bought 54,936 Inhibrx shares in Q1 2026, an estimated $4.07M.
  • Inhibrx made up 0.29% of SummitTX Capital's portfolio in Q1 2026, its #74 holding.
  • SummitTX Capital first reported a position in Inhibrx in Q3 2025 and has held it in 3 quarters since.
  • 135 funds tracked by Wall St. Rank held Inhibrx as of Q1 2026.

Based on SummitTX Capital's 13F filing for Q1 2026, filed 15 May 2026.